Siemens Healthcare Diagnostics, Inc. – FDA Warning Letter, Jan 4, 2012

The FDA issued a Warning Letter to Siemens Healthcare Diagnostics, Inc. following a 2011-2012 inspection of their East Walpole, MA facility. The inspection found their in vitro diagnostic devices, including iPTH, adulterated due to non-conformity with Quality System (QS) regulation (21 CFR Part 820). The firm's FDA 483 response was not reviewed due to late submission. Key QS violations included inadequate procedures for device design validation and verification (21 CFR 820.30(g), 820.30(f)), process validation (21 CFR 820.75(a)), and corrective and preventive actions (CAPA) (21 CFR 820.100(a)). The firm also failed to adequately document CAPA activities (21 CFR 820.100(b)), establish proper complaint handling procedures (21 CFR 820.198(a)), and investigate complaints thoroughly (21 CFR 820.198(c)). Further deficiencies involved inadequate product identification (21 CFR 820.60) and device history records (21 CFR 820.184). Additionally, devices were misbranded due to Medical Device Reporting (MDR) failures (21 CFR Part 803), specifically not submitting 15 malfunction reports within 30 days (21 CFR 803.50(a)(2)) and failing to submit supplemental information (21 CFR 803.56). Violations under 21 CFR Part 806 included not reporting device corrections or removals (21 CFR 806.10(a)(1)) and inadequate documentation for not reporting such actions (21 CFR 806.20(b)(4)). The FDA requires prompt correction. Non-compliance may lead to regulatory actions like seizure, injunction, civil money penalties, and impact on federal contracts and device approvals. A written response detailing corrective and preventive actions, with a timetable, is required within fifteen business days. The firm is responsible for ensuring overall compliance.